These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 29066501)

  • 1. Knockdown of BRCA2 enhances cisplatin and cisplatin-induced autophagy in ovarian cancer cells.
    Wan B; Dai L; Wang L; Zhang Y; Huang H; Qian G; Yu T
    Endocr Relat Cancer; 2018 Jan; 25(1):69-82. PubMed ID: 29066501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.
    Chan KK; Wong OG; Wong ES; Chan KK; Ip PP; Tse KY; Cheung AN
    Int J Cancer; 2018 Sep; 143(6):1456-1469. PubMed ID: 29663364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma.
    Sung PL; Jan YH; Lin SC; Huang CC; Lin H; Wen KC; Chao KC; Lai CR; Wang PH; Chuang CM; Wu HH; Twu NF; Yen MS; Hsiao M; Huang CY
    Oncotarget; 2016 Jan; 7(4):4036-47. PubMed ID: 26716408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Knockdown of MALAT1 enhances chemosensitivity of ovarian cancer cells to cisplatin through inhibiting the Notch1 signaling pathway.
    Bai L; Wang A; Zhang Y; Xu X; Zhang X
    Exp Cell Res; 2018 May; 366(2):161-171. PubMed ID: 29548748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calpain system protein expression and activity in ovarian cancer.
    Zhang S; Deen S; Storr SJ; Chondrou PS; Nicholls H; Yao A; Rungsakaolert P; Martin SG
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):345-361. PubMed ID: 30448882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of cisplatin resistance in clear cell carcinoma of the ovary.
    Itamochi H; Kigawa J; Akeshima R; Sato S; Kamazawa S; Takahashi M; Kanamori Y; Suzuki M; Ohwada M; Terakawa N
    Oncology; 2002; 62(4):349-53. PubMed ID: 12138243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Claudin-4: a potential therapeutic target in chemotherapy-resistant ovarian cancer.
    Yoshida H; Sumi T; Zhi X; Yasui T; Honda K; Ishiko O
    Anticancer Res; 2011 Apr; 31(4):1271-7. PubMed ID: 21508375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells.
    Zhu X; Shen H; Yin X; Long L; Chen X; Feng F; Liu Y; Zhao P; Xu Y; Li M; Xu W; Li Y
    Oncotarget; 2017 Jun; 8(24):39154-39166. PubMed ID: 28388577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of copper transporter expression with platinum resistance in epithelial ovarian cancer.
    Yoshida H; Teramae M; Yamauchi M; Fukuda T; Yasui T; Sumi T; Honda K; Ishiko O
    Anticancer Res; 2013 Apr; 33(4):1409-14. PubMed ID: 23564780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovarian serous carcinomas acquire cisplatin resistance and increased invasion through downregulation of the high-temperature-required protein A2 (HtrA2), following repeated treatment with cisplatin.
    Soyama H; Miyamoto M; Takano M; Aoyama T; Matsuura H; Sakamoto T; Takasaki K; Kuwahara M; Kato K; Yoshikawa T; Iwahashi H; Tsuda H; Furuya K
    Med Oncol; 2017 Nov; 34(12):201. PubMed ID: 29168038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of somatic mutations in BRCA2 BRC domain with chemotherapy sensitivity and survival in high grade serous ovarian cancer.
    Zhang G; Zhang J; Zhu Y; Liu H; Shi Y; Mi K; Li M; Zhao Q; Huang Z; Huang J
    Exp Cell Res; 2021 Sep; 406(1):112742. PubMed ID: 34302857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
    Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
    Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Musashi-2 is a novel regulator of paclitaxel sensitivity in ovarian cancer cells.
    Lee J; An S; Choi YM; Lee J; Ahn KJ; Lee JH; Kim TJ; An IS; Bae S
    Int J Oncol; 2016 Nov; 49(5):1945-1952. PubMed ID: 27600258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upregulation of phosphorylated cofilin 1 correlates with taxol resistance in human ovarian cancer in vitro and in vivo.
    Li M; Yin J; Mao N; Pan L
    Oncol Rep; 2013 Jan; 29(1):58-66. PubMed ID: 23064469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells.
    Mir R; Tortosa A; Martinez-Soler F; Vidal A; Condom E; Pérez-Perarnau A; Ruiz-Larroya T; Gil J; Giménez-Bonafé P
    Int J Cancer; 2013 Apr; 132(7):1525-36. PubMed ID: 22961628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagy.
    He J; Yu JJ; Xu Q; Wang L; Zheng JZ; Liu LZ; Jiang BH
    Autophagy; 2015; 11(2):373-84. PubMed ID: 25650716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts.
    Washington MN; Suh G; Orozco AF; Sutton MN; Yang H; Wang Y; Mao W; Millward S; Ornelas A; Atkinson N; Liao W; Bast RC; Lu Z
    Cell Death Dis; 2015 Aug; 6(8):e1836. PubMed ID: 26247722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression and effects of modulation of the K2P potassium channels TREK-1 (KCNK2) and TREK-2 (KCNK10) in the normal human ovary and epithelial ovarian cancer.
    Innamaa A; Jackson L; Asher V; van Schalkwyk G; Warren A; Keightley A; Hay D; Bali A; Sowter H; Khan R
    Clin Transl Oncol; 2013 Nov; 15(11):910-8. PubMed ID: 23479219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MUS81 is associated with cell proliferation and cisplatin sensitivity in serous ovarian cancer.
    Xie S; Zheng H; Wen X; Sun J; Wang Y; Gao X; Guo L; Lu R
    Biochem Biophys Res Commun; 2016 Aug; 476(4):493-500. PubMed ID: 27255997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary.
    Sasano T; Mabuchi S; Kuroda H; Kawano M; Matsumoto Y; Takahashi R; Hisamatsu T; Sawada K; Hashimoto K; Isobe A; Testa JR; Kimura T
    Mol Cancer Res; 2015 Apr; 13(4):795-806. PubMed ID: 25519148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.